Formaat : 10mg
Synonyms: Taurodeoxychloic acid
| Description | Taurodeoxycholic acid (Taurodeoxychloic acid) is a bile acid taurine conjugate of deoxycholic acid, a human metabolite that stabilizes mitochondrial membranes and reduces the formation of free radicals.Taurodeoxycholic acid inhibits apoptosis by blocking calcium-mediated apoptotic pathways and by activation of caspase-12. Taurodeoxycholic acid has neuroprotective activity and has been used to study 3-nitropropionic acid-induced or stabilized hereditary Huntington's chorea (HD). |
| In vitro | Taurodeoxycholic acid (50, 100 μM; 4 h) increases oligonuclear DNA cleavage and nuclear apoptosis in primary human hepatocytes.[1] Taurodeoxycholic acid (400 μM; 18-24 h) increases DNA fragmentation and PARP cleavage and induces apoptosis in human liver-derived Huh7 cells.[2] |
| In vivo | Taurodeoxycholic acid (50 mg/kg; i.p.; once daily for 34 days; Huntington's disease model in mice) prevents neuropathology and associated behavioral deficits in a rat model of Huntington's disease (HD).[3] Taurodeoxycholic acid (500 mg/kg; subcutaneous injection; every 3 days for 7 weeks; Huntington's disease model in mice) resulted in a significant reduction in striatal neuropathology in R6/2 transgenic HD mice.[4] |
| Synonyms | Taurodeoxychloic acid |
| Molecular Weight | 499.7 |
| Formula | C26H45NO6S |
| Cas No. | 516-50-7 |
| Smiles | C[C@@]12[C@]([C@]3([C@@]([C@]4(C)[C@](CC3)(C[C@H](O)CC4)01)(C[C@@H]1O)01)01)(CC[C@@]2([C@@H](CCC(NCCS(=O)(=O)O)=O)C)01)01 |
| Storage | Keep away from direct sunlight,Store at low temperature, Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 50 mg/mL (100.06 mM), Sonication is recommended.  | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (4 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
Note : The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density. | ||||||||||||||||||||||||||||||||||||
For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, and a total of 10 animals are to be administered, using a formulation of 
10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH2O , the resulting working solution concentration would be 2 mg/mL.Dissolve 2 mg of the compound in 100 μL DMSO to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO stock solution to 400 µL PEG300 and mix thoroughly until the solution becomes clear.
2) Add 50 µL Tween 80 and mix well until fully clarified.
3) Add 450 µL Saline,PBS or ddH2O and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|
